Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
CNY 19.25
(-3.12%)
CNY 19.25
(-3.12%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.9 Billion CNY | 25.75% |
| 2022 | 1.51 Billion CNY | 11.91% |
| 2021 | 1.35 Billion CNY | 16.53% |
| 2020 | 1.16 Billion CNY | -11.04% |
| 2019 | 1.3 Billion CNY | 32.75% |
| 2018 | 983.77 Million CNY | 50.19% |
| 2017 | 655 Million CNY | 34.4% |
| 2016 | 487.35 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 430.4 Million CNY | -31.38% |
| 2024 Q2 | 412 Million CNY | -4.27% |
| 2024 Q3 | 343.66 Million CNY | -16.59% |
| 2023 FY | 1.9 Billion CNY | 25.75% |
| 2023 Q1 | 527.26 Million CNY | 15.01% |
| 2023 Q2 | 386.71 Million CNY | -26.66% |
| 2023 Q3 | 363.99 Million CNY | -5.88% |
| 2023 Q4 | 627.2 Million CNY | 72.31% |
| 2022 Q4 | 458.44 Million CNY | 41.87% |
| 2022 Q1 | 399.16 Million CNY | -9.95% |
| 2022 Q3 | 323.14 Million CNY | -3.34% |
| 2022 Q2 | 334.29 Million CNY | -16.25% |
| 2022 FY | 1.51 Billion CNY | 11.91% |
| 2021 Q3 | 279.33 Million CNY | -13.44% |
| 2021 Q1 | 308.48 Million CNY | -11.5% |
| 2021 FY | 1.35 Billion CNY | 16.53% |
| 2021 Q4 | 443.25 Million CNY | 58.68% |
| 2021 Q2 | 322.71 Million CNY | 4.61% |
| 2020 Q3 | 237.58 Million CNY | -25.01% |
| 2020 Q4 | 348.56 Million CNY | 46.71% |
| 2020 FY | 1.16 Billion CNY | -11.04% |
| 2020 Q1 | 258.72 Million CNY | -40.83% |
| 2020 Q2 | 316.82 Million CNY | 22.46% |
| 2019 Q1 | 275.79 Million CNY | 0.0% |
| 2019 FY | 1.3 Billion CNY | 32.75% |
| 2019 Q2 | 335 Million CNY | 21.47% |
| 2019 Q4 | 437.24 Million CNY | 69.55% |
| 2019 Q3 | 257.87 Million CNY | -23.02% |
| 2018 FY | 983.77 Million CNY | 50.19% |
| 2017 FY | 655 Million CNY | 34.4% |
| 2016 FY | 487.35 Million CNY | 0.0% |